Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

Cancer & Antibody Conjugates Patent Landscape Report: Evaluating 3,761 Patent Families, Linker-Payload Technologies, and Strategies of Roche, Daiichi Sankyo, Gilead, and AstraZeneca

Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term

Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer

DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk

Merck pairs ADCs with Keytruda in women’s cancer push

VERAXA Biotech Designates Raju Willener as CFO